Synthesis of a Glycogen Synthase Kinase-3 Inhibitor
Nicholas A. Magnus, Christopher P. Ley, Pamela M. Pollock, James P. Wepsiec
Abstract
Nicholas A. Magnus, Christopher P. Ley, Pamela M. Pollock, James P. Wepsiec
Abstract
Significance Glycogen synthase kinase-3 (GSK-3) is involved in signaling from the insulin receptor and inhibitors of it are expected to lower plasma glucose similar to insulin. It is under development for the treatment of type 2 diabetes. The target bisarylmaleimide was synthesized in seven steps in 33% overall yield from 5-fluoroindole ( A ).
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Significance Glycogen synthase kinase-3 (GSK-3) is involved in signaling from the insulin receptor and inhibitors of it are expected to lower plasma glucose similar to insulin. It is under development for the treatment of type 2 diabetes. The target bisarylmaleimide was synthesized in seven steps in 33% overall yield from 5-fluoroindole ( A ).
Key concepts: GSK-3, Glycogen synthase, Chemistry, Glycogen, Insulin receptor, Insulin, GSK3B, Biochemistry